MILAN, ITALY and CHIASSO, SWITZERLAND, June 1, 2023 – Dompé farmaceutici S.p.A. (“Dompé”) and FarmaMondo Group announced they have extended their agreement whereby FarmaMondo Group becomes Dompé’s distribution partner for Oxervate (cenegermin) in additional selected countries.
The agreement names FarmaMondo Group as the exclusive provider of Oxervate (cenegermin) in countries outside of the United States, Canada, Italy, China and Switzerland.
“Dompé is strongly committed to providing access to innovative treatments to improve the lives of many patients now living with highly unmet medical needs – said Eriona Gjinukaj, Chief Operating Officer at Dompé – We are pleased to continue to offer a Managed Access Program with the support of a globally respected player as FarmaMondo, in accordance with the local requirements”.
Yaron Spigel, Chairman of FarmaMondo Group, commented: “The agreement represents an enormous opportunity for FarmaMondo to treat patients suffering from a rare disease through our specialty care services by following an established robust process while adhering to local regulation”.
Healthcare professionals in countries outside of the United States, Canada, Italy, China, Switzerland, can learn details about obtaining Oxervate by contacting FarmaMondo at:
cenegermin@farmamondo.com
0041 916 97 6371
About Oxervate
Oxervate (cenegermin) is a recombinant human nerve growth factor (rhNGF) that is structurally identical to the nerve growth factor (NGF) protein that is made in the human body, including in the ocular tissues[1]. Oxervate (cenegermin) has been evaluated in clinical trials and it has received regulatory approval in the United States, Europe, Switzerland, Israel, China, Canada and Australia.
- Dua HS, Said DG, Messmer EM, et al. Neurotrophic keratopathy. Prog Retin Eye Res. 2018;66:107- 131. (Link to: https://pubmed.ncbi.nlm.nih.gov/29698813/)
About Dompé
Dompé is a private, rapidly scaling international biopharmaceutical company founded in Milan, Italy, with a 130-year legacy of medical innovation. The R&D department of the company is anchored by EXSCALATE, a structure-based virtual screening platform developed in-house that leverages one of the most powerful supercomputing and artificial intelligence platforms in the world. Today, Dompé employs more than 800 people worldwide and maintains a US commercial operations hub in the San Francisco Bay Area.
For any further information about Dompé Managed Access Programs, visit www.dompe.com
About FarmaMondo Group
FarmaMondo is a fast-growing Swiss group dedicated to providing Biopharma, healthcare professionals and their patients around the world with greater access to medicines. The Group offers high value market access and specialty distribution services, through a unique infrastructure and geographical footprint, targeted to enable patient access to Specialty Medicines in key Emerging Markets through a combined approach of Named Patient access and full commercialization.
